ストックスクリーナーアプリを入手
1.87
5.56%
-0.11
アフターアワーズ：
1.92
0.05
+2.67%
前日終値:
$1.98
開ける：
$1.93
24時間の取引高:
120.89K
Relative Volume:
0.69
時価総額：
$188.77M
収益：
-
当期純損益:
$-60.14M
株価収益率:
-2.6357
EPS:
-0.7095
ネットキャッシュフロー:
$-68.17M
1週間 パフォーマンス:
-11.79%
1か月 パフォーマンス:
-26.38%
6か月 パフォーマンス:
-50.53%
1年 パフォーマンス:
-36.82%
1日の値動き範囲:
$1.87
$1.96
1週間の範囲:
$1.87
$2.15
52週間の値動き範囲:
$1.87
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
ACIU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.87 | 188.77M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | BTIG Research | Buy |
| 2019-02-01 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-04 | 開始されました | UBS | Buy |
| 2018-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 開始されました | Credit Suisse | Outperform |
| 2016-10-18 | 開始されました | Jefferies | Buy |
| 2016-10-18 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Ac Immune Sa (ACIU) 最新ニュース
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewswire
Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks
AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance
AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World
AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView
AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks
AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq
AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan
AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World
New Strong Buy Stocks for March 5th - Nasdaq
AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire
AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR
AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve
AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St
High Growth Tech Stocks in the United States - Simply Wall St
Japan deals big, wins approvals, mulls CGT; Korea, Australia, too - BioWorld Online
AC Immune SA's (NASDAQ:ACIU) last week's 11% decline must have disappointed retail investors who have a significant stake - Simply Wall St
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership - TipRanks
AC Immune (NASDAQ:ACIU) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 - Yahoo Finance
AC Immune's ABATE Trial Shows Positive Safety Data in Down Syndrome - Investing.com Canada
AC Immune Announces Promising Safety Data for Down Syndrome Therapy - TipRanks
Ac Immune Sa (ACIU) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):